Viglya wishes to establish transparent and open communication with its stakeholders. This section offers new and updated information regarding the company and the life science sector.


AEMPS: Solicitudes de autorización de comercialización de medicamentos de uso humano. Monográfico de bases legales

Sorry, this entry is only available in Español.


Comments are closed.

EMA: Good practice guide on recording, coding, reporting and assessment of medication errors
EMA: Risk minimisation strategy for high strength and fixed combination insulin products, addendum to the good practice guide on risk minimisation and prevention of medication errors
EMA: Good practice guide on risk minimisation and prevention of medication errors
EMA: Preventing medication errors in the European Union
ANSM: Application du règlement européen relatif aux essais cliniques de médicaments: Mise en place par l’ANSM d’une phase pilote
ANSM: Recommandations du PRAC concernant le risque cardiovasculaire des médicaments contenant de l’ibuprofène utilisés à fortes doses
AEMPS: Riesgo cardiovascular de dosis altas de ibuprofeno o dexibuprofeno: recomendaciones de uso
EMA: Draft qualification opinion of qualification of exacerbations of chronic pulmonary disease tool (EXACT), and EXACT-respiratory symptoms measure (E-RS) for evaluating treatment outcomes in clinical trials in chronic pulmonary disease
EMA: Meeting highlights from the PRAC 7-10 April 2015
EMA: PRAC recommends updating advice on use of high dose ibuprofen